keyword
MENU ▼
Read by QxMD icon Read
search

Diffuse large cell lymphoma

keyword
https://www.readbyqxmd.com/read/28938652/correlation-between-apparent-diffusion-coefficient-adc-and-cellularity-is-different-in-several-tumors-a-meta-analysis
#1
Alexey Surov, Hans Jonas Meyer, Andreas Wienke
The purpose of this meta-analysis was to provide clinical evidence regarding relationship between ADC and cellularity in different tumors based on large patient data. Medline library was screened for associations between ADC and cell count in different tumors up to September 2016. Only publications in English were extracted. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement (PRISMA) was used for the research. Overall, 39 publications with 1530 patients were included into the analysis...
August 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/28938556/abcg2-and-ncf4-polymorphisms-are-associated-with-clinical-outcomes-in-diffuse-large-b-cell-lymphoma-patients-treated-with-r-chop
#2
Duo Liu, Nan Wu, Haiming Sun, Mei Dong, Tianzhu Guo, Peng Chi, Guofu Li, Donglin Sun, Yan Jin
The impact of pharmacogenetics on predicting survival in diffuse large B-cell lymphoma (DLBCL) remains unclear. We tested 337 DLBCL patients treated with rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for 9 single nucleotide polymorphisms from 6 genes (CD20, FCGR2A, NAD(P)H, ABCC2, ABCG2 and CYP3A5). Patients who carried the NCF4 rs1883112 GG genotype showed significantly shorter progression-free survival (PFS) (P = 0.023) and event-free survival (EFS) (P < 0.001) comparing with A allele...
August 29, 2017: Oncotarget
https://www.readbyqxmd.com/read/28936073/butterfly-tumor-of-the-corpus-callosum-clinical-characteristics-diagnosis-and-survival-analysis
#3
Thara Tunthanathip, Sanguansin Ratanalert, Sakchai Sae-Heng, Thakul Oearsakul
BACKGROUND: The pathologies implicate the bilateral corpus callosum that builds the butterfly pattern on axial view. These tumors have seldom been investigated for both clinical manifestations and outcome. OBJECTIVE: The objective of this study was to describe the clinical characteristics and outcomes of the butterfly tumor and to identify the predictive factors associated with survival outcome. METHODS: A retrospective study of 50 butterfly tumor was conducted between 2003 and 2016...
August 2017: Journal of Neurosciences in Rural Practice
https://www.readbyqxmd.com/read/28935843/efficacy-and-safety-of-subcutaneous-and-intravenous-rituximab-plus-cyclophosphamide-doxorubicin-vincristine-and-prednisone-in-first-line-diffuse-large-b-cell-lymphoma-the-randomized-mabease-study
#4
Pieternella Lugtenburg, Irit Avivi, Henriette Berenschot, Osman Ilhan, Jean Pierre Marolleau, Arnon Nagler, Antonio Rueda, Monica Tani, Mehmet Turgut, Stuart Osborne, Rodney Smith, Michael Pfreundschuh
Intravenous rituximab plus chemotherapy is standard treatment for diffuse large B-cell lymphoma. A subcutaneous formulation of rituximab is expected to simplify and shorten drug preparation and administration, and to reduce treatment burden. MabEase (NCT01649856) examined efficacy, safety and patient satisfaction with subcutaneous rituximab plus chemotherapy in treatment-naïve patients with diffuse large B-cell lymphoma. Patients were randomized 2:1 to subcutaneous rituximab (intravenous 375 mg/m(2) cycle 1; subcutaneous 1,400 mg cycles 2-8) or intravenous rituximab (375 mg/m(2) cycles 1-8) plus cyclophosphamide, doxorubicin, vincristine, and prednisone every 14 or 21 days...
September 21, 2017: Haematologica
https://www.readbyqxmd.com/read/28933643/economic-burden-following-allogeneic-hematopoietic-stem-cell-transplant-in-patients-with-diffuse-large-b-cell-lymphoma
#5
Richard T Maziarz, Yanni Hao, Annie Guerin, Genevieve Gauthier, Marjolaine Gauthier-Loiselle, Simu K Thomas, Lamis Eldjerou
This study describes short-term and long-term healthcare resource utilization (HRU) and costs following an allogeneic hematopoietic stem cell transplant (HSCT) in adult patients with diffuse large B-cell lymphoma (DLBCL) in a real-world setting. Among 101 patients with DLBCL receiving an allogeneic HSCT, HRU and direct healthcare costs for up to three years after the allogeneic HSCT are described. HRU and costs were substantial, with the most intensive HRU and highest healthcare costs observed during the first year after HSCT (38 inpatient days; 68 days with office visits and average healthcare costs of $455,741)...
September 21, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28933554/rational-targeting-of-cellular-cholesterol-in-diffuse-large-b-cell-lymphoma-dlbcl-enabled-by-functional-lipoprotein-nanoparticles-a-therapeutic-strategy-dependent-on-cell-of-origin
#6
Jonathan S Rink, Shuo Yang, Osman Cen, Tim Taxter, Kaylin M McMahon, Sol Misener, Amir Behdad, Richard Longnecker, Leo I Gordon, C Shad Thaxton
Cancer cells have altered metabolism and, in some cases, an increased demand for cholesterol. It is important to identify novel, rational treatments based on biology, and cellular cholesterol metabolism as a potential target for cancer is an innovative approach. Toward this end, we focused on diffuse large B-cell lymphoma (DLBCL) as a model because there is differential cholesterol biosynthesis driven by B-cell receptor (BCR) signaling in germinal center (GC) versus activated B-cell (ABC) DLBCL. To specifically target cellular cholesterol homeostasis, we employed high-density lipoprotein-like nanoparticles (HDL NP) that can generally reduce cellular cholesterol by targeting and blocking cholesterol uptake through the high-affinity HDL receptor, scavenger receptor type B-1 (SCARB1)...
September 21, 2017: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/28932613/primary-pulmonary-lymphoma-presenting-with-superior-vena-cava-syndrome-in-a-young-female
#7
Divya Salhan, Prakash Verma, Tun Win Naing, Ebad Ur Rehman, Saroj Kandel, Danillo Enriquez, Joseph Quist, Frances Schmidt
Primary Pulmonary Diffuse Large B Cell Lymphoma (PPDLBCL) is an extremely rare entity, which exhibits an aggressive behavior by compressing local blood vessels. It represents only 0.04% of all lymphoma cases and is extremely rare in young age. We present a case of a primary pulmonary lymphoma with superior vena cava syndrome (SVCS) in a young female. 27-year-old African American female presented with fever, cough, and facial puffiness for 2 weeks and unintentional weight loss. Chest examination showed decreased breath sounds and dullness on percussion on right side...
2017: Case Reports in Pulmonology
https://www.readbyqxmd.com/read/28932610/pneumocystis-pneumonia-in-non-hiv-pregnant-women-receiving-chemotherapy-for-malignant-lymphoma-two-case-reports
#8
Yuki Fukutani, Yoshitsugu Chigusa, Eiji Kondoh, Kaoru Kawasaki, Shingo Io, Noriomi Matsumura
Pneumocystis pneumonia (PCP) is a life-threatening opportunistic infection that sometimes occurs in immunocompromised patients with human immunodeficiency virus (HIV). Here, we report two extremely rare cases of PCP in non-HIV pregnant women who underwent chemotherapy for malignant lymphoma. Case  1 is a 34-year-old primigravida who was diagnosed with Hodgkin's lymphoma. She received ABVD chemotherapy and developed PCP at 37 weeks of gestation. After the onset of PCP, emergent cesarean section was performed due to a nonreassuring fetal status...
2017: Case Reports in Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28930682/chemically-induced-degradation-of-the-oncogenic-transcription-factor-bcl6
#9
Nina Kerres, Steffen Steurer, Stefanie Schlager, Gerd Bader, Helmut Berger, Maureen Caligiuri, Christian Dank, John R Engen, Peter Ettmayer, Bernhard Fischerauer, Gerlinde Flotzinger, Daniel Gerlach, Thomas Gerstberger, Teresa Gmaschitz, Peter Greb, Bingsong Han, Elizabeth Heyes, Roxana E Iacob, Dirk Kessler, Heike Kölle, Lyne Lamarre, David R Lancia, Simon Lucas, Moriz Mayer, Katharina Mayr, Nikolai Mischerikow, Katja Mück, Christoph Peinsipp, Oliver Petermann, Ulrich Reiser, Dorothea Rudolph, Klaus Rumpel, Carina Salomon, Dirk Scharn, Renate Schnitzer, Andreas Schrenk, Norbert Schweifer, Diane Thompson, Elisabeth Traxler, Roland Varecka, Tilman Voss, Alexander Weiss-Puxbaum, Sandra Winkler, Xiaozhang Zheng, Andreas Zoephel, Norbert Kraut, Darryl McConnell, Mark Pearson, Manfred Koegl
The transcription factor BCL6 is a known driver of oncogenesis in lymphoid malignancies, including diffuse large B cell lymphoma (DLBCL). Disruption of its interaction with transcriptional repressors interferes with the oncogenic effects of BCL6. We used a structure-based drug design to develop highly potent compounds that block this interaction. A subset of these inhibitors also causes rapid ubiquitylation and degradation of BCL6 in cells. These compounds display significantly stronger induction of expression of BCL6-repressed genes and anti-proliferative effects than compounds that merely inhibit co-repressor interactions...
September 19, 2017: Cell Reports
https://www.readbyqxmd.com/read/28928469/activation-of-mir-34a-5p-sirt1-p66shc-pathway-contributes-to-doxorubicin-induced-cardiotoxicity
#10
Jie-Ning Zhu, Yong-Heng Fu, Zhi-Qin Hu, Wen-Yu Li, Chun-Mei Tang, Hong-Wen Fei, Hui Yang, Qiu-Xiong Lin, De-Ming Gou, Shu-Lin Wu, Zhi-Xin Shan
The molecular mechanisms underlying anthracyclines-induced cardiotoxicity have not been well elucidated. MiRNAs were revealed dysregulated in the myocardium and plasma of rats received Dox treatment. MicroRNA-34a-5p (miR-34a-5p) was verified increased in the myocardium and plasma of Dox-treated rats, but was reversed in rats received Dox plus DEX treatments. Human miR-34a-5p was also observed increased in the plasma of patients with diffuse large B-cell lymphoma after 9- and 16-week epirubicin therapy. Up-regulation of miR-34a-5p was observed in Dox-induced rat cardiomyocyte H9c2 cells...
September 19, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28927150/upfront-high-dose-chemotherapy-combined-with-autologous-stem-cell-transplantation-potential-survival-benefit-for-patients-with-high-risk-diffuse-large-b-cell-lymphoma
#11
Aya Nakaya, Shinya Fujita, Atsushi Satake, Takahisa Nakanishi, Yoshiko Azuma, Yukie Tsubokura, Masaaki Hotta, Hideaki Yoshimura, Kazuyoshi Ishii, Tomoki Ito, Shosaku Nomura
In patients with diffuse large B-cell lymphoma (DLBCL) classified as high-intermediate risk or high risk using the International Prognosis Index, the efficacy of high-dose chemotherapy combined with upfront autologous stem cell transplantation (HDT/ASCT) remains controversial in the rituximab era. In the present study, 27 patients who had been treated with HDT/ASCT in an upfront setting were retrospectively analyzed, and compared with 77 patients with similar characteristics who had received conventional chemotherapy without HDT/ASCT (the non-upfront setting)...
September 2017: Oncology Letters
https://www.readbyqxmd.com/read/28927145/bcl2-ki-67-index-predict-survival-in-germinal-center-b-cell-like-diffuse-large-b-cell-lymphoma
#12
Yun-Long Tang, Yan Zhou, Ling-Ling Cheng, Yong-Zhong Su, Chun-Bin Wang
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma. BCL2 apoptosis regulator (BCL2) and marker of proliferation Ki-67 (Ki-67) are established prognostic markers, which have traditionally been assessed separately in DLBCL. However, no studies have evaluated the prognostic value of the combination of BCL2 and Ki-67 index. Thus, the present study aimed to analyze the prognostic value of combination of these two markers. Immunohistochemical analysis was used to assess the expression of BCL2 and Ki-67 in 274 cases of DLBCL...
September 2017: Oncology Letters
https://www.readbyqxmd.com/read/28926410/outcomes-for-hiv-associated-diffuse-large-b-cell-lymphoma-in-the-modern-cart-era
#13
Caroline Besson, Remi Lancar, Sophie Prevot, Michele Algarte-Genin, Pierre Delobel, Fabrice Bonnet, Marie-Caroline Meyohas, Marialuisa Partisani, Lucie Oberic, Jean Gabarre, Cécile Goujard, François Boue, Paul Coppo, Regis Costello, Houria Hendel-Chavez, Nawel Mekerri, Gabriella Dos Santos, Christian Recher, Richard Delarue, Rene-Olivier Casasnovas, Yassine Taoufik, Nicolas Mounier, Dominique Costagliola
OBJECTIVE: Non-Hodgkin's lymphoma (NHL) remains among the most frequent malignancies in persons living with HIV (PLWHIV). Survival among patients with HIV-associated diffuse large B-cell lymphoma (DLBCL), the most frequent NHL subtype, has improved markedly in recent years. We aimed to analyze characteristics and outcomes of DLBCL in HIV-infected patients in the era of modern combined antiretroviral therapy (cART). DESIGN: PLWHIV with lymphoma were prospectively enrolled in the French ANRS-CO16 Lymphovir cohort between 2008 and 2015...
September 18, 2017: AIDS
https://www.readbyqxmd.com/read/28926365/primary-cutaneous-diffuse-large-b-cell-lymphoma-leg-type-with-spontaneous-regression-after-biopsy
#14
Gabriel Marrero-Alemán, Társila Montenegro-Dámaso, Yeray Peñate
Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) represents approximately 20% of cutaneous B lymphomas with an intermediate prognosis. Spontaneous regression is uncommon; there are only 2 published cases. An 83-year-old woman presented 2 orange erythematous nodules on the back of her right leg with an elastic consistency, infiltrated, painful to the touch, and of an 8-month evolution. A histological examination revealed a dense cellular dermo-hypodermic infiltrate sparing the papillary dermis, composed of large cells with immunoblast and centroblast morphology and frequent mitosis...
October 2017: American Journal of Dermatopathology
https://www.readbyqxmd.com/read/28924126/development-of-epstein-barr-virus-related-primary-diffuse-large-b-cell-lymphoma-of-the-central-nervous-system-in-a-patient-with-peripheral-t-cell-lymphoma-not-otherwise-specified-after-mogamulizumab-treatment
#15
Hiroaki Tanaka, Hanako Aoki, Yasumasa Sugita, Ryo Shimizu, Katsunari Kiko, Hidetoshi Mochida, Yoshio Suzuki
Mogamulizumab is a defucosylated humanized anti-CC chemokine receptor type 4 (CCR4) antibody that exerts an anti-tumor immune effect against various tumors through a suppressive effect on regulatory T-cells. We herein report a patient with peripheral T-cell lymphoma who developed Epstein-Barr virus (EBV)-related primary diffuse large B-cell lymphoma of the central nervous system (CNS DLBCL) after mogamulizumab therapy. Our experience should alert physicians to the possibility of the development of EBV-related CNS DLBCL in patients treated for primary lymphoma and suggests that the anti-tumor immune effect of mogamulizumab is ineffective for the prophylaxis of EBV-related lymphomas...
September 15, 2017: Internal Medicine
https://www.readbyqxmd.com/read/28922443/primary-hepatic-lymphoma-complicated-by-a-hepatic-inflammatory-pseudotumor-and-tumor-forming-pancreatitis
#16
Rena Kaneko, Hiroyuki Mitomi, Natsuko Nakazaki, Yuichiro Yano, Masazumi Ogawa, Yuzuru Sato
BACKGROUND: Hepatic inflammatory pseudotumor (IPT) is considered to be benign in biological behavior, and its malignant transformation is extremely rare. There has only been one published case of primary hepatic lymphoma complicated by hepatic IPT. CASE PRESENTATION: A 73-year-old man presented with obstructive jaundice and a pancreatic head mass. Histology of the mass revealed chronic pancreatitis with lymphoid follicle formation, leading to a diagnosis of a suspicion of follicular pancreatitis...
September 2017: Journal of Gastrointestinal and Liver Diseases: JGLD
https://www.readbyqxmd.com/read/28921160/gp2013-a-rituximab-biosimilar
#17
Hannah A Blair
GP2013 is the second biosimilar of the reference monoclonal anti-CD20 antibody rituximab to be approved in the EU. It is approved for use in all indications for which reference rituximab is approved, including follicular lymphoma (FL), diffuse large B-cell non-Hodgkin's lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis (RA), granulomatosis with polyangiitis and microscopic polyangiitis. GP2013 has similar physicochemical and pharmacodynamic properties to those of reference rituximab, and the pharmacokinetic biosimilarity of the agents has been shown in patients with RA...
September 18, 2017: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/28918104/peripheral-blood-lymphocyte-to-monocyte-ratio-at-relapse-predicts-outcome-for-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-in-the-rituximab-era
#18
Daisuke Katoh, Yotaro Ochi, Tomohiro Yabushita, Yuichiro Ono, Nobuhiro Hiramoto, Satoshi Yoshioka, Noboru Yonetani, Akiko Matsushita, Hisako Hashimoto, Shuichiro Kaji, Yukihiro Imai, Takayuki Ishikawa
BACKGROUND: Patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) have a poor prognosis, even in the rituximab era. Several studies have reported the clinical importance of the peripheral blood lymphocyte-to-monocyte ratio (LMR) in various malignancies, including lymphoma. However, the prognostic value of the LMR in relapsed/refractory DLBCL has not been well evaluated. The purpose of the present study was to investigate whether the LMR at relapse can predict clinical outcomes for relapsed/refractory DLBCL patients treated with rituximab...
August 14, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28915427/breast-lymphoma-in-a-patient-with-b-cell-non-hodgkin-lymphoma-a-case-report-study
#19
Spyridon Marinopoulos, Panagiotis Safioleas, Lamprini Skorda, Eleni Vassilopoulou, Flora Zagouri, Maria Sotiropoulou, Peter Drakakis, Constantine Dimitrakakis
INTRODUCTION: Breast involvement in Non Hodgkin Lymphoma is a rare entity as it accounts for 2.2% of all extranodal lymphomas. PRESENTATION OF CASE: A 59-year-old woman was referred to our Breast Unit because of two nodules of the right breast newly discovered during her annual mammography. Moreover, during the physical examination, a red-brown itchy lump of the scalp was discovered. The punch biopsies of the scalp lesion and ultrasound-guided core biopsies of both nodules of the right breast, revealed the presence of diffuse large B-cell Non Hodgkin Lymphoma in all tissue specimen sites...
September 7, 2017: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/28915212/22-cases-of-bia-alcl-awareness-and-outcome-tracking-from-the-italian-ministry-of-health
#20
Campanale Antonella, Boldrini Rosaria, Marletta Marcella
BACKGROUND: To date, 359 cases of anaplastic large cell lymphoma in women with breast implants (BIA-ALCL) worldwide have been reported out of more than 10 million implanted patients but Health Care Authorities suspect this is a possible underestimation and the limited number of cases makes it difficult to clarify its etiology. The General Directorate of Medical Devices and Pharmaceutical Services of the Italian Ministry of Health (IMoH) has examined and studied the Italian BIA-ALCL cases, and the aim of this study is to report on the knowledge and experience gained on this new emerging disease...
September 13, 2017: Plastic and Reconstructive Surgery
keyword
keyword
6710
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"